MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a value of the control of the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a value of the control of the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a value of the control of the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a value of the control of the control

no persons are require	ed to respond to a collection of illionnesses.	
Under the Paperwork Reduction Act of 1995, no persons are require	Complete if Known	APR 2 7 2004
Substitute for form 1449B/PTO	Application Number 10//77,144 1	· .
INFORMATION DISCLOSURE	Filing Date	RA
STATEMENT BY APPLICANT	First Named IIIV	
	Group An Unit Unassigned SANTE	D SHEET
(use as many sheets as necessary)	Attorney Docket Number 034536-1210	
Sheet 1 of 6	Milenia	

				FO	REIGN PATENT DOCUMENT	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner	Cite	Office	oreign Patent Docum	nent nd Code ⁵ (known)	Name of Patentee or Applicant of Cited Documents	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	To
nitials*	-		92/01050		NEW YORK UNIVERSITY	01-23-1992		+
00 /	A1	wo	94/01119	A1	NATIONAL UNIVERSITY OF SINGAPORE	01-20-1994		-
8/	A2	-	,	A2	FAMITALIA CARLO ERBA	02-17-1994		
	А3	wo	94/03610		S.R.L. NEW YORK UNIVERSITY	04-28-1994		
& /	A4	wo	94/09037	A1	MEDICAL CENTER	04-20 .50		

VD			
		NON PATENT LITERATURE DOCUMENTS	8
	Cito	of the author (in CAPITAL LETTERS), title of the article (which page(s), volume-issue number(s),	_
Examiner Initials*	Cite No.1	include name of the journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, serial, symposium, catalog, etc.) described item (book, magazine, journal, symposium, symposium, symposium, symposium, symposium, symposium, s	
	A5	63-704 (1967)	_
	A6	1/31 hilman epideimore o role in	
%	A7	CANNOLL et al., "The Expression of a novel receptor-type tyrosine phosphatase suggests a role in morphogenesis and plasticity of the nervous system," Development Brain Research, Oct. 15, 1993, pp. morphogenesis and plasticity of the nervous system, Development Brain Research, Oct. 15, 1993, pp. 293-298, vol. 75, No. 2	
9/	A8	293-298, vol. 75, No. 2 CARNEY et al., "Monoclonal antibody specific for an activated RAS protein," Proc. Nat. Acad. Sci. USA, Oct. 1986, pp. 7485-7489, vol. 83 CHARBONNEAU et al., "Human placenta protein-tyrosine-phosphatase: Amino acid sequence and CHARBONNEAU et al., "Human placenta proteins," Proc. Natl. Acad. Sci. USA 86:5252-5256 (1989)	
	A9	CHARBONNEAU et al., "Human placenta protein-tyrosine-phosphatase: Amino acid sequential	1
	A10	relationship to a family of receptor-like proteins, Processing Pro	+
	A1	phosphatase," <u>Proc. Natl. Acad. Sci. USA</u> 65.7 102 Proc. Natl. Acad. Sci. USA 65.7 102 Proc. Natl. Acad. CHERNOFF et al., "Cloning of a cDNA for a major human protein-tyrosine-phosphatase," <u>Proc. Natl. Acad. Sci. USA</u> , 87:2735-2739 (1990)	_1

			1/21/0-6
	<i>M</i>	Date Considered	173.10
Examiner	considered, whether or not citation is in conformance with MPEP 809.	Draw line through citation if	not in conformance and not
Signature	considered, whether or not citation is in conformance with MFEF 555.		ando AMPO

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the their statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the their statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the chief information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, PO Box 1450, and the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, PO Box 1450, and the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, PO Box 1450, and the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, PO Box 1450, and the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, PO Box 1450, and the Information Officer, U.S. Patent and Trademark Officer, PO Box 1450, and the Informati

Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

7	Substitute for form	1449B/	PTO	Complete if Known			
	INFORMATION DE	SCLO	SURE	Application Number	10/777,144		
	STATEMENT BY	APPLI	CANT	Filing Date	02/13/2004		
				First Named Inventor	Joseph SCHLESSINGER		
			•	Group Art Unit	Unassigned 1644		
(use as many sheets as necessary)				Examiner Name	Unassigned SANJOD JALLA		
Sheet	2	of	6	Attorney Docket Number	034536-1210		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [®]
	A12	CHURCH, et al., "Genomic Sequencing", <u>Proc. Natl. Acad. Sci.</u> , vol. 81, pp. 1994-1995, (1984)	
	A13	COOL et al., "cDNA isolated from a human T-cell library encodes a member of the protein-tyrosine-phosphatase family," Proc. Natl. Acad. Sci. USA 86:5257-5261 (1989)	
-	A14	COOL et al., "Overexpression of a T-cell protein tyrosine phosphatase (PTPase) in BHK Cells," <u>FASEB J.</u> 4:A2078 (abstr. 2230) (1990)	
	A15	CYERT and THORNER, "Putting it on and taking if off: Phosphoprotein phosphatase involvement in cell cycle regulation," Cell 57:891-893 (1989)	
	A16	DAUM et al., "Characterization of a human recombinant receptor-linked protein tyrosine phosphatase," <u>J. Biol, Chem.</u> , 266:12211-12215 (1991)	
	A17	FISCHER et al., "Protein tyrosine phosphatases: A diverse family of intracellular and transmembrane enzymes," Science 253:401-406 (1991)	
·	A18	GEBBINK et al., "Cloning, expression and chromosomal localization of a new putative receptor-like protein tyrosine phosphatase," FEBS Lett. 290:123-130 (1991)	
	A19	GEORGE and PARKER, "Preliminary characterization of phosphotyrosine phosphatase activities in human peripheral blood lymphocytes: Identification of CD45 as a phosphotyrosine phosphatase," <u>J. Cell Biochem.</u> 42:71-81 (1990).	
	A20	GU et al., "Identification, cloning, and expression of a cytosolic megakaryocyte protein-tyrosine-phosphatase with sequence homology to cytoskeletal protein 4.1," Proc. Natl. Acad. Sci. USA 88:5867-5871 (1991)	
& /	A21	GUAN et al., "Protein Tyrosine Phosphatase Activity of an Essential Virulence Determinant in Yersinia," Science, Aug. 3, 1990, pp. 553-556, vol. 249.	
	A22	GUAN et al., "Cloning and expression of a protein-tyrosine-phosphatase," Proc. Natl. Acad. Sci. USA 87:1501-1505 (1990)	
	A23	HALL et al., "Complete exon-intron organization of the human leukocyte common antigen (CD45) gene," <u>J. Immunol.</u> 141:2781-2787 (1988)	
	A24	HARIHARAN et al., "Cloning and characterization of a receptor-class phosphotyrosine phosphatase gene expressed on central nervous system axons in Drosophila melanogaster," Proc. Natl. Acad. Sci. USA 88:11266-11270 (1991)	

Examiner Signature	Date Considered	1/31/06

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

¹ Unique citation designation number. 2See attached Kinds of U.S. Patent Documents, 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.
*Applicant is to place a check mark here if English tanguage Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.

	Substitute for form	1449B	PTO	1	Complete if Known
	INFORMATION D	ISCLO	SURE	Application Number	10/777,144
	STATEMENT BY	APPLI	CANT	Filing Date	02/13/2004
				First Named Inventor	Joseph SCHLESSINGER
				Group Art Unit	Unassigned 1644
	(use as many sheets	as ne	cessary)	Examiner Name	Unassigned SANTOD JALLA
Sheet	3	of	6	Attorney Docket Number	034536-1210

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁵
	A25	HUNTER, "Protein-tyrosine phosphatases: The other side of the coin," Cell 58:1013-1016 (1989)	
	A26	JIRIK et al., "Cloning and chromosomal assignment of a widely expressed human receptor-like protein-tyrosine phosphatase," FEBS Lett. 273:239-242 (1990)	
	A27	JIRIK et al., "Cloning of a novel receptor-linked protein tyrosine phosphatase from a human hepatoblastoma cell line," <u>FASEB J.</u> 4A:2082 (Abstr. 2253) (1990)	
	A28	JONES et al., "Phosphotyrosyl-protein phosphatases," <u>J. Biol. Chem.</u> 264:7747-7753 (1989)	
	A29	KAPLAN et al., "Cloning of three human tyrosine phosphatases reveals a multigene family of receptor-linked protein-tyrosine-phosphatases expressed in brain," <u>Proc. Natl. Acad. Sci. USA</u> 87:7000-7004 (1990)	
	A30	KIENER and MITTLER, "CD45-protein tyrosine phosphatase cross-linking inhibits T-cell receptor CD3-mediated activation in human T-cells," <u>J. Immunol.</u> 143:23-28 (1989)	
	A31	KLARLUND, "Transformation of cells by an inhibitor of phosphatases acting on phosphotyrosine in proteins," Cell 41:707-717 (1985)	
8	A32	KRUEGER and SAITO, "A human transmembrane protein-tyrosine-phosphatase, PTP, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases," <u>Proc. Natl. Acad. Sci. USA</u> , 1992, pp. 7417-7421, vol. 89, No. 16.	
	A33	KRUEGER et al., "Structural diversity and evolution of human receptor-like protein tyrosine phosphatases," EMBO J. 9:3241-3252 (1990)	
	A34	LEVY et al., "The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system," <u>Journal of Biological Chemistry</u> , May 15, 1993, pp. 10573-10581, vol. 268, No. 14	
	A35	LOMBROSO et al., "Molecular characterization of a protein-tyrosine-phosphatase enriched in striatum," Proc. Natl. Acad. Sci. USA 88:7242-7246 (1991)	
	A36	MATTHEWS et al., "Characterization of hemotopoietic intracellular protein tyrosine phosphatases: Description of a phosphatase containing an SH2 Domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences," Molec. and Cell. Biol. 12:2396-2405 (1992)	

Examiner Signature	Date Considered	1/31/06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

7	Substitute fo	r form 1449B	/PTO	Complete if Known			
	INFORMATI	ON DISCLO	SURE	Application Number	10/777,144		
STATEMENT BY APPLICANT				Filing Date	02/13/2004		
				First Named Inventor	Joseph SCHLE	SSINGER	
				Group Art Unit	Unassigned	1644	
(use as many sheets as necessary)				Examiner Name	Unassigned	SANJOO JALLA	
Sheet	4	of	6	Attomey Docket Number	034536-1210		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [®]
	A37	MATTHEWS et al., "Identification of an additional member of the protein-tyrosine-phosphatase family: Evidence for alternative splicing in the tryosine phosphatase domain," <u>Proc. Natl. Acad. Sci. USA</u> 87:4444-4448 (1990)	
	A38	MUSTELIN et al., "Rapid activation of the T-cell tyrosine protein kinase pp56lck by the CD45 phosphotyrosine phosphatase," Proc. Natl. Acad. Sci. USA 86:6302-6306 (1989)	
	A39	OHAGI et al., "Sequence of a cDNA encoding human LRP (leukocyte common antigen-related peptide)," Nucl. Acids Res. 18:7159 (1990)	
	A40	OSTERGAARD et al., "Expression of CD45 alters phosphorylation of the lck-encoded tyrosine protein kinase in murine lymphoma T-cell lines," <u>Proc. Natl. Acad. Sci. USA</u> 86:8959-8963 (1989)	
	A41	PALLEN et al., "Purification of a phosphotyrosine phosphatase that dephosphorylates the epidermal growth factor receptor autophosphorylation sites," <u>Ann. N.Y. Acad. Sci.</u> 551:299-308 (1988)	
	A42	PINGEL and THOMAS, "Evidence that the leukocyte-common antigen is required for antigen-induced T lymphocyte proliferation," Cell 58:1055-1065 (1989)	
	A43	PLUTZKY et al., "Isolation of a src homology 2-containing tyrosine phosphatase," <u>Proc. Natl. Acad. Sci. USA</u> 89:1123-1127 (1992)	
!	A44	POT and DIXON, "A thousand and two protein tyrosine phosphatases," <u>Biochem. Biophys. Acta.</u> 1136:35-43 (1992)	
	A45	RALPH et al., "Structural variants of human T200 glycoprotein (leukocyte-common antigen)," <u>EMBO J.</u> 6:1251-1257 (1987)	
	A46	SAIKI et al., "Enzymatic amplification of .betaglobin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia," SCIENCE, Dec. 20, 1985, pp. 1350-1354, vol. 230	
`	A47	SAP et al., "Cloning and expression of a widely expressed receptor tyrosine phosphatase," <u>Proc. Natl. Acad. Sci. USA</u> 87:6112-6116 (1990)	
8	A48	SCOPES, <u>Protein Purification: Principles and Practice</u> , Springer-Verlag, New York, 1987, TABLE OF CONTENTS ONLY	
	A49	SHEN et al., "A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases," Nature 352:736-739 (1991)	

Examiner Signature	8	Date Considered	1/31/06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			/PTO	Complete if Known		
			SURE	Application Number	10/777,144	
			ICANT	Filing Date	02/13/2004	
				First Named Inventor	Joseph SCHLESSINGER	
				Group Art Unit	Unassigned 1644	
			cessary)	Examiner Name	Unassigned (AN JOO JALLA	
Sheet	5	of	6	Attorney Docket Number	034536-1210	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T°
	A50	STREULI et al., "A family of receptor-linked protein tyrosine phosphatases in humans and Drosophila," <u>Proc. Natl. Acad. Sci. USA</u> 86:8698-8702 (1989)	
	A51	STREULI et al., "A new member of the immunoglobulin superfamily that has a cytoplasmic region homologous to the leukocyte common antigen," <u>J. Exp. Med.</u> 168:1523-1530 (1988)	
A52 STREULI et al., "Differential usage of three exons generates at least five different mRNAs encod leukocyte common antigens," <u>J. Exp. Med.</u> 166:1548-1566 (1987)			
A53 STREULI et al., "Distinct functional roles of the two intracellular phosphatase like domain linked protein tyrosine phosphatases LCA and LAR," EMBO Journal 9:2399-2407 (1990)		STREULI et al., "Distinct functional roles of the two intracellular phosphatase like domains of the receptor-linked protein tyrosine phosphatases LCA and LAR," EMBO Journal 9:2399-2407 (1990)	
,	A54	THOMAS et al., "ABA, A novel member of the tyrosine phosphatase family," <u>FASEB J.</u> 4:A2078 (Abstr. 3140) (1990)	
	A55	THOMAS, "The leukocyte common antigen family," Ann. Rev. Immunol. 7:339-369 (1989)	
	A56	TONKS and CHARBONNEAU, "Protein tyrosine dephosphorylation and signal transduction," <u>Trends in Biochem. Sci.</u> 14:497-500 (1989)	
A57 TONKS et al., "CD45, an integral membrane protein tyrosine phosphatase," <u>J. Biol. Chem.</u> 265: 10680 (1990)		TONKS et al., "CD45, an integral membrane protein tyrosine phosphatase," <u>J. Biol. Chem.</u> 265:10674-10680 (1990)	
A58 TONKS et al., "Demonstration that the leukocyte common antigen CD45 is a protein tyrosin Biochemistry 27:8695-8701 (1988)		TONKS et al., "Demonstration that the leukocyte common antigen CD45 is a protein tyrosine phosphatase," Biochemistry 27:8695-8701 (1988)	
	A59	TONKS et al., "Purification of the major protein-tyrosine-phosphatases of human placenta," <u>J. Biol. Chem.</u> 263:6722-6730 (1988)	
	A60	TOWBIN, et al., "Electrophoretic Transfer of Proteins From Polyacrylamide Gels To Nitrocellulose Sheets: Procedure And Some Applications", <u>Proc. Natl. Acad. Sci.</u> , vol. 76, No. 9, pp. 4350-4354, (1979)	
	A61	TSAI et al., "Isolation and characterization of temperature-sensitive and thermostable mutants of the human receptor-like protein tyrosine phosphatase LAR," <u>J. Biol. Chem.</u> 266(16):10534-10543 (1991)	
	A62	YANG and TONKS, "Isolation of a cDNA clone encoding a human protein-tyrosine phosphatase with homology to the cytoskeletal-associated proteins band 4.1, ezrin, and talin," Proc. Natl. Acad. Sci. USA 88:5949-5953 (1991)	

Examiner Signature	B	Date Considered	1/34/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

¹ Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control

the stage of 1995 no persons are requir	ed to respond to a collection or internation
Under the Paperwork Reduction Act of 1995, no persons are require	
Substitute for form 1449B/PTO	Application Number 10/777,144 02/13/2004
INFORMATION DISCLOSURE	Filing Date Joseph SCHLESSINGER Joseph SCHLESSINGER
STATEMENT DIVIN	Group Art Unit Ungeringer CANTOO JACCA
(use as many sheets as necessary)	Examiner Name Attorney Docket Number 034536-1210
Sheet 6 of 6	Attorney Docker (Caraca)

	6	of 6 Anomey Boston
et	0	
		(the purpor (in CAPITAL LETTERS), title of the date, page(s), volume-issue number(s).
xaminer iitials*	Cite No. ¹	publisher, city and/or county throng publisher city and/or city and/
	A63	
	A64	(1992) ZHENG, et al., "Cell Transformation and Activation of pp60_sup.c-src By Overexpression of a Protein Tyrosine Phophatase," Nature, vol. 359, No. 6393, pp. 336-339 (1992)
_	_	
_		
_		
_		
1	1	

		Date Considered	1/31/06
Examiner Signature	the ther or not citation is in conformance with MPEP 6	109. Draw line through citation	on if not in conformance and not
 J.g., 515.5	t ubother or not citation is in comotive		ORNAD

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to Complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to Complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to Complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to Complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, and the amount of time you are required to Complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, and the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, and the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, and the Information Officer of the Information Officer, U.S. Patent and Trademark Officer, PO Box 1450, and the Information Officer of the Information Officer, U.S. Patent and Trademark Officer, PO Box 1450, and the Information Officer of the Information Officer, U.S. Patent and Trademark Offi

Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.30 if possible. ⁶Applicant is to place a check mark here if a possible of the serial number of the patent document. The properties of the patent document under WIPO Standard ST.30 if possible of the patent document is the patent document. The patent document is the patent document in the patent document under WIPO Standard ST.30 if possible of the patent document is the patent document. The patent document is the patent document is the patent document in the patent document under WIPO Standard ST.30 if possible of the patent document is the patent document in the patent document in the patent document is the patent document in the